Pharmaceuticals & Biotechnology
Valuation | |
|---|---|
| Market Cap | 1.38 LCr |
| Price/Earnings (Trailing) | 60.76 |
| Price/Sales (Trailing) | 10.91 |
| EV/EBITDA | 34.78 |
| Price/Free Cashflow | 60.57 |
| MarketCap/EBT | 45.88 |
| Enterprise Value | 1.4 LCr |
Fundamentals | |
|---|---|
Growth & Returns | |
|---|---|
| Price Change 1W | 6.6% |
| Price Change 1M | 6% |
| Price Change 6M | 16.3% |
| Price Change 1Y | 41.4% |
| 3Y Cumulative Return | 42% |
| 5Y Cumulative Return | 27.4% |
| 7Y Cumulative Return | 25.2% |
| 10Y Cumulative Return | 20.4% |
| Revenue (TTM) |
| 12.65 kCr |
| Rev. Growth (Yr) | 15.8% |
| Earnings (TTM) | 2.27 kCr |
| Earnings Growth (Yr) | 26.2% |
Profitability | |
|---|---|
| Operating Margin | 24% |
| EBT Margin | 24% |
| Return on Equity | 26.89% |
| Return on Assets | 14.64% |
| Free Cashflow Yield | 1.65% |
| Cash Flow from Investing (TTM) | -540 Cr |
| Cash Flow from Operations (TTM) | 2.58 kCr |
| Cash Flow from Financing (TTM) | -2.3 kCr |
| Cash & Equivalents | 621 Cr |
| Free Cash Flow (TTM) | 1.97 kCr |
| Free Cash Flow/Share (TTM) | 58.33 |
Balance Sheet | |
|---|---|
| Total Assets | 15.52 kCr |
| Total Liabilities | 7.07 kCr |
| Shareholder Equity | 8.45 kCr |
| Current Assets | 6.17 kCr |
| Current Liabilities | 4.43 kCr |
| Net PPE | 3.46 kCr |
| Inventory | 2.47 kCr |
| Goodwill | 340 Cr |
Capital Structure & Leverage | |
|---|---|
| Debt Ratio | 0.17 |
| Debt/Equity | 0.31 |
| Interest Coverage | 13.67 |
| Interest/Cashflow Ops | 12.09 |
Dividend & Shareholder Returns | |
|---|---|
| Dividend/Share (TTM) | 32 |
| Dividend Yield | 0.83% |
| Shares Dilution (1Y) | 0.00% |
| Shares Dilution (3Y) | 0.00% |
Size: It is among the top 200 market size companies of india.
Growth: Good revenue growth. With 35.2% growth over past three years, the company is going strong.
Smart Money: Smart money has been increasing their position in the stock.
Momentum: Stock price has a strong positive momentum. Stock is up 6% in last 30 days.
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Balance Sheet: Strong Balance Sheet.
Profitability: Very strong Profitability. One year profit margin are 18%.
Past Returns: Outperforming stock! In past three years, the stock has provided 42% return compared to 12.4% by NIFTY 50.
No major cons observed.
Size: It is among the top 200 market size companies of india.
Growth: Good revenue growth. With 35.2% growth over past three years, the company is going strong.
Smart Money: Smart money has been increasing their position in the stock.
Momentum: Stock price has a strong positive momentum. Stock is up 6% in last 30 days.
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Balance Sheet: Strong Balance Sheet.
Profitability: Very strong Profitability. One year profit margin are 18%.
Past Returns: Outperforming stock! In past three years, the stock has provided 42% return compared to 12.4% by NIFTY 50.
No major cons observed.
Investor Care | |
|---|---|
| Dividend Yield | 0.83% |
| Dividend/Share (TTM) | 32 |
| Shares Dilution (1Y) | 0.00% |
| Earnings/Share (TTM) | 67.12 |
Financial Health | |
|---|---|
| Current Ratio | 1.39 |
| Debt/Equity | 0.31 |
Technical Indicators | |
|---|---|
| RSI (14d) | 63.52 |
| RSI (5d) | 87.61 |
| RSI (21d) | 54.3 |
| MACD Signal | Buy |
| Stochastic Oscillator Signal | Sell |
| SharesGuru Signal | Buy |
| RSI Signal | Hold |
| RSI5 Signal | Sell |
| RSI21 Signal | Hold |
| SMA 5 Signal | Buy |
| SMA 10 Signal |
Updated May 4, 2025
Summary of Torrent Pharmaceuticals's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.
Understand Torrent Pharmaceuticals ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.
| Shareholder Name | Holding % |
|---|---|
| TORRENT INVESTMENTS LIMITED (FORMERLY KNOWN AS TORRENT INVESTMENTS PRIVATE LIMITED) | 68.31% |
| NPS TRUST | 2.44% |
| HDFC MUTUAL FUND - HDFC PHARMA AND HEALTHCARE FUND | 1.19% |
| MEHTA FAMILY TRUST 1 | 0% |
| MEHTA FAMILY TRUST 2 | 0% |
| MEHTA FAMILY TRUST 3 | 0% |
| MEHTA FAMILY TRUST 4 |
Detailed comparison of Torrent Pharmaceuticals against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.
Ticker | Name | Mkt Cap | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | Sun Pharmaceutical Industries | 4.08 LCr | 58.94 kCr | +1.90% | 0.00% | 37.37 | 6.92 | - | - |
| CIPLA | Cipla | 1.09 LCr | 29.37 kCr |
Comprehensive comparison against sector averages
TORNTPHARM metrics compared to Pharmaceuticals
| Category | TORNTPHARM | Pharmaceuticals |
|---|---|---|
| PE | 60.76 | 33.87 |
| PS | 10.91 | 4.67 |
| Growth | 11.2 % | 10.8 % |
Torrent Pharmaceuticals is a prominent pharmaceuticals company with the stock ticker TORNTPHARM and a significant market capitalization of Rs. 112,871.4 Crores. Founded in 1959 and based in Ahmedabad, India, the company was previously known as Trinity Laboratories before changing its name in 1971.
The company specializes in the research, development, manufacturing, and marketing of generic pharmaceutical formulations. Its operations span across multiple countries, including India, the United States, Brazil, Germany, and other international markets.
Torrent Pharmaceuticals offers a wide range of products across various therapeutic areas such as:
Additionally, the company provides contract manufacturing services.
With a trailing twelve-month revenue of Rs. 11,374 Crores, Torrent Pharmaceuticals has demonstrated strong profitability, achieving a profit of Rs. 1,862 Crores over the past year. The company has experienced a revenue growth of 33.9% over the last three years.
Investors benefit from its commitment to returning value, as Torrent Pharmaceuticals distributes dividends with a yield of 1.62% per year. In the previous 12 months, the company returned a dividend of Rs. 54 per share. Torrent Pharmaceuticals is a subsidiary of Torrent Investments Private Limited.
This is an informational page just to provide a quick 'first look' at the stock. You must do your own deeper research. Know your risk appetite. Consult a SEBI-registered financial advisor before making any investment decisions.
| Buy |
| SMA 20 Signal | Buy |
| SMA 50 Signal | Buy |
| SMA 100 Signal | Buy |
TORNTPHARM vs Pharmaceuticals (2021 - 2026)
High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years
High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years
Torrent Pharmaceuticals is currently trading 1.08% higher at Rs 3,284.75.
Investor Presentation • 13 Feb 2026 Investor Presentation on financial results Q3 FY 2025-26 |
Analyst / Investor Meet • 13 Feb 2026 Audio Recording of Conference call with Analysts / Investors on Financial Results for the quarter and nine months ended 31st december, 2025 |
Analyst / Investor Meet • 11 Feb 2026 Analyst call details attached |
Acquisition • 03 Feb 2026 Intimation of acquisition of equity shares of J.B. Chemicals & Pharmaceuticals Limited |
Analyst / Investor Meet • 02 Feb 2026 Post Quarterly Financial Result Conference call with investors / analyst |
Change in Management • 30 Jan 2026 |
This information is AI-generated and may contain inaccuracies. Please verify from multiple sources.
| 0% |
| ANITA SUDHIR MEHTA | 0% |
| SAPNA SAMIR MEHTA | 0% |
| JINAL SUDHIR MEHTA | 0% |
| VARUN SUDHIR MEHTA | 0% |
| SHAAN MEHTA | 0% |
| BBIPM4098Q | 0% |
| SUDHIR UTTAMLAL MEHTA | 0% |
| SAMIR UTTAMLAL MEHTA | 0% |
Distribution across major stakeholders
Distribution across major institutional holders
| -3.00% |
| -7.20% |
| 24.07 |
| 3.73 |
| - |
| - |
| DRREDDY | Dr. Reddy's Lab | 1.06 LCr | 36.09 kCr | +8.00% | +6.00% | 18.98 | 2.94 | - | - |
| LUPIN | Lupin | 1.01 LCr | 26.49 kCr | +2.10% | +12.80% | 21.84 | 3.83 | - | - |
| AUROPHARMA | Aurobindo Pharma | 68.8 kCr | 33.73 kCr | +1.00% | +4.70% | 19.73 | 2.04 | - | - |
| -0.2% |
| 2,466 |
| 2,471 |
| 2,403 |
| 2,252 |
| 2,151 |
| 2,212 |
| Profit Before exceptional items and Tax | 2.5% | 824 | 804 | 738 | 689 | 691 | 661 |
| Exceptional items before tax | 21.4% | -10 | -13 | 0 | -24 | 0 | 0 |
| Total profit before tax | 2.9% | 814 | 791 | 738 | 665 | 691 | 661 |
| Current tax | 4.7% | 244 | 233 | 201 | 184 | 153 | 156 |
| Deferred tax | -94.1% | -65 | -33 | -11 | -17 | 35 | 52 |
| Total tax | -10.6% | 179 | 200 | 190 | 167 | 188 | 208 |
| Total profit (loss) for period | 7.5% | 635 | 591 | 548 | 498 | 503 | 453 |
| Other comp. income net of taxes | 77.9% | -16 | -76 | -2 | 36 | -70 | -25 |
| Total Comprehensive Income | 20.2% | 619 | 515 | 546 | 534 | 433 | 428 |
| Earnings Per Share, Basic | 8% | 18.77 | 17.45 | 16.19 | 14.71 | 14.88 | 13.37 |
| Earnings Per Share, Diluted | 8% | 18.77 | 17.45 | 16.19 | 14.71 | 14.88 | 13.37 |
| Debt equity ratio | - | - | - | - | 04 | - | - |
| Debt service coverage ratio | - | - | - | - | 0.0491 | - | - |
| Interest service coverage ratio | - | - | - | - | 0.1366 | - | - |
| 12.8% |
| 1,636 |
| 1,451 |
| 1,251 |
| 1,098 |
| 1,097 |
| 1,062 |
| Finance costs | -29.8% | 213 | 303 | 298 | 236 | 339 | 430 |
| Depreciation and Amortization | -0.1% | 760 | 761 | 672 | 602 | 610 | 607 |
| Other expenses | 8.2% | 2,230 | 2,061 | 1,840 | 1,636 | 1,487 | 1,552 |
| Total Expenses | 5.6% | 7,080 | 6,707 | 6,200 | 5,480 | 5,203 | 5,288 |
| Profit Before exceptional items and Tax | 37.4% | 2,634 | 1,917 | 1,577 | 1,466 | 1,366 | 1,117 |
| Exceptional items before tax | - | -24 | 0 | 0 | 0 | 0 | 0 |
| Total profit before tax | 36.2% | 2,610 | 1,917 | 1,577 | 1,466 | 1,366 | 1,117 |
| Current tax | 68.2% | 541 | 322 | 274 | 253 | 248 | 192 |
| Deferred tax | -24.1% | 181 | 238 | 251 | 222 | -20 | -14 |
| Total tax | 29% | 722 | 560 | 525 | 475 | 228 | 178 |
| Total profit (loss) for period | 39.2% | 1,888 | 1,357 | 1,052 | 991 | 1,138 | 939 |
| Other comp. income net of taxes | -240% | -41 | 31 | -78 | 1 | 110 | -115 |
| Total Comprehensive Income | 33.1% | 1,847 | 1,388 | 974 | 992 | 1,248 | 824 |
| Earnings Per Share, Basic | 40.1% | 55.79 | 40.1 | 31.07 | 29.295 | 33.62 | 27.73 |
| Earnings Per Share, Diluted | 40.1% | 55.79 | 40.1 | 31.07 | 29.295 | 33.62 | 27.73 |
| Debt equity ratio | - | 034 | - | - | - | - | - |
| Debt service coverage ratio | - | 0.0408 | - | - | - | - | - |
| Interest service coverage ratio | - | 0.1443 | - | - | - | - | - |
| 33% |
| 485 |
| 365 |
| 247 |
| 204 |
| 235 |
| 675 |
| Goodwill | 0% | 324 | 324 | 324 | 324 | 324 | 324 |
| Non-current investments | 7.3% | 441 | 411 | 403 | 322 | 218 | 205 |
| Loans, non-current | 50% | 4 | 3 | 3 | 3 | 2 | 3 |
| Total non-current financial assets | 6% | 457 | 431 | 424 | 342 | 238 | 220 |
| Total non-current assets | -1.6% | 8,353 | 8,493 | 8,450 | 8,635 | 8,704 | 8,946 |
| Total assets | 3.8% | 13,325 | 12,842 | 12,408 | 12,377 | 12,623 | 12,872 |
| Borrowings, non-current | -15.1% | 867 | 1,021 | 1,414 | 1,604 | 1,944 | 2,332 |
| Total non-current financial liabilities | -7.1% | 1,026 | 1,104 | 1,442 | 1,620 | 1,963 | 2,360 |
| Provisions, non-current | 8.3% | 366 | 338 | 289 | 282 | 260 | 245 |
| Total non-current liabilities | -4.1% | 2,177 | 2,270 | 2,525 | 2,559 | 2,784 | 3,007 |
| Borrowings, current | -26.2% | 1,127 | 1,526 | 1,127 | 1,729 | 1,733 | 2,234 |
| Total current financial liabilities | -13.2% | 2,254 | 2,598 | 1,978 | 2,697 | 2,723 | 3,183 |
| Provisions, current | 14.6% | 237 | 207 | 210 | 171 | 172 | 151 |
| Current tax liabilities | 70.8% | 124 | 73 | 73 | 30 | 0 | - |
| Total current liabilities | -9.6% | 2,693 | 2,980 | 2,357 | 2,989 | 2,974 | 3,409 |
| Total liabilities | -7.2% | 4,870 | 5,250 | 4,882 | 5,548 | 5,758 | 6,416 |
| Equity share capital | 0% | 169 | 169 | 169 | 169 | 169 | 169 |
| Total equity | 11.4% | 8,455 | 7,592 | 7,526 | 6,829 | 6,865 | 6,456 |
| Total equity and liabilities | 3.8% | 13,325 | 12,842 | 12,408 | 12,377 | 12,623 | 12,872 |
| -4.8% |
| 3,064 |
| 3,218 |
| 2,538 |
| 2,380 |
| - |
| - |
| Income taxes paid (refund) | 50.9% | 490 | 325 | 272 | 240 | - | - |
| Net Cashflows From Operating Activities | -11% | 2,574 | 2,893 | 2,266 | 2,140 | - | - |
| Cashflows used in obtaining control of subsidiaries | - | 78 | 0 | 1,963 | 24 | - | - |
| Cash payment for investment in partnership firm or association of persons or LLP | - | 10 | 0 | 0 | 0 | - | - |
| Proceeds from sales of PPE | -45.2% | 18 | 32 | 155 | 3 | - | - |
| Purchase of property, plant and equipment | 29.7% | 446 | 344 | 571 | 108 | - | - |
| Dividends received | -102% | 0 | 50 | 0 | 0 | - | - |
| Interest received | -100% | 1 | 4 | 9 | 4 | - | - |
| Other inflows (outflows) of cash | -101.1% | 0 | 90 | 43 | -35 | - | - |
| Net Cashflows From Investing Activities | -58.6% | -470 | -296 | -2,327 | -160 | - | - |
| Proceeds from borrowings | -200% | 0 | 2 | 2,193 | 0 | - | - |
| Repayments of borrowings | -36.3% | 788 | 1,236 | 972 | 1,043 | - | - |
| Payments of lease liabilities | 100% | 9 | 5 | 5 | 17 | - | - |
| Dividends paid | 6.7% | 1,083 | 1,015 | 863 | 677 | - | - |
| Interest paid | -30.7% | 224 | 323 | 272 | 240 | - | - |
| Net Cashflows from Financing Activities | 18.3% | -2,104 | -2,577 | 81 | -1,977 | - | - |
| Net change in cash and cash eq. | -105.3% | 0 | 20 | 20 | 3 | - | - |
General • 27 Jan 2026 Shifting of Registered Office |